KalshiVerifica disponibilitàKYC richiesto2% di commissioneDati di risoluzione verificatiDiscretamente calibratoProbabilità implicita attuale
Sì 97%+30.0pt
Qualità del mercato
45 / 100
Bassa qualitàVolume 24h
539,3 €
Liquidità
594,2 €
Bassa liquiditàBid / Ask
72.0% / 80.0%
Spread
8.0 pt
Spread ampioDati di mercato
Aggiornato 14 minuti fa
17 giu 26, 21:30 UTC1 gen 27, 04:59 UTC
Trend
Mercati Correlati
Domande correlate per il contesto, non un confronto tra contratti equivalenti.
FDA decision: Ivonescimab by Summit Therapeutics (in 2026)
KalshiFDA decision: Bepirovirsen by GlaxoSmithKline (in 2026)
KalshiFDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (in 2026)
KalshiEbola pandemic in 2026?
PolymarketHantavirus pandemic in 2026?
PolymarketFDA approves skin cancer vaccine by which date?
PolymarketRegole
If the FDA's decision on Saroglitazar by Zydus Therapeutics in 2026 is a full approval or an accelerated approval, the market resolves to Yes.
Si regola tramite:AppliedXL
- This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
- Saroglitazar (sold under the brand name Lipaglyn in India) is an oral small-molecule drug developed by Zydus Therapeutics that is designed to simultaneously activate two molecular switches in the body — called PPAR-alpha and PPAR-gamma — which together regulate how the body handles fats and sugars.
- Think of it like a dual-dial thermostat for metabolism: turning up both dials at once aims to reduce harmful lipid buildup and improve insulin sensitivity more effectively than nudging just one dial.
- In the EPICS-III trial , it is being evaluated as a treatment for primary biliary cholangitis, a liver disease distinct from its original metabolic indications.
Mercati aperti
Health & MedicinePOLYMARKETHantavirus pandemic in 2026?
- No-0.1pt97%
- Yes+0.1pt3%
- Volume totale
- 15,6 Mln €
- Volume 24h
- 18,3K €
KALSHIWill WHO declare Hantavirus a Public Health Emergency of International Concern this Year?
- No96%
- Yes+1.9pt4%
- Volume totale
- 1,6 Mln €
- Volume 24h
- 5,2K €
KALSHIWhen will Intellia Therapeutics submit a BLA for Lonvo-z?
- before October+64.0pt98%
- before 2027+22.0pt98%
- before December+30.0pt98%
+3 altri esiti
POLYMARKETFDA approves skin cancer vaccine by which date?
- December 31,+6.0pt65%
- September+2.0pt41%
- June28%
- Volume totale
POLYMARKETNew pandemic in 2026?
- No+0.5pt94%
- Yes-0.5pt6%
- Volume totale
- 916K €
- Volume 24h
- 1,5K €
KALSHIMeasles cases in 2026?
- Above 300099%
- Above 400097%
- Above 6000-2.0pt57%
+2 altri esiti
- Volume totale
- 863,6K €
- Volume 24h
- 1K €
- Ebola pandemic in 2026?
- Will 3 mg THC beverages be federally legal to sell?
- Ebola pandemic in 2026?
- Measles cases in U.S. in 2026?
- FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026)
- When will Heidi Overton be confirmed as Commissioner of the FDA?
- What will the average number of measles cases be during Trump's term?
- Will the FDA approve any psychedelic substance for medical use this year?
- When will the FDA reclassify BPC-157 to Category 1?
- Will the FDA approve CagriSema?
- When will Compass Pathways submit a NDA for COMP360 psilocybin?
Domande frequenti
- Quali sono le probabilità attuali per FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)?
- Kalshi quota Yes al 97% al 8 settembre 2026.
- Quando si risolve FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)?
- FDA decision: Saroglitazar by Zydus Therapeutics (in 2026) dovrebbe risolversi il 1 gennaio 2027.
- Come viene liquidato FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)?
- Kalshi liquida questo mercato come segue: If the FDA's decision on Saroglitazar by Zydus Therapeutics in 2026 is a full approval or an accelerated approval, the market resolves to Yes.